CRVO vs. NVCT, RPTX, IXHL, INCR, IMAB, PDSB, AMLX, RNAC, SGMT, and SYRS
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include Nuvectis Pharma (NVCT), Repare Therapeutics (RPTX), Incannex Healthcare (IXHL), InterCure (INCR), I-Mab (IMAB), PDS Biotechnology (PDSB), Amylyx Pharmaceuticals (AMLX), Cartesian Therapeutics (RNAC), Sagimet Biosciences (SGMT), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical preparations" industry.
CervoMed (NASDAQ:CRVO) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
CervoMed currently has a consensus target price of $57.50, suggesting a potential upside of 137.60%. Nuvectis Pharma has a consensus target price of $21.00, suggesting a potential upside of 221.10%. Given Nuvectis Pharma's higher possible upside, analysts plainly believe Nuvectis Pharma is more favorable than CervoMed.
25.2% of CervoMed shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 2.0% of CervoMed shares are held by insiders. Comparatively, 38.9% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CervoMed has higher revenue and earnings than Nuvectis Pharma.
CervoMed has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
In the previous week, Nuvectis Pharma had 19 more articles in the media than CervoMed. MarketBeat recorded 26 mentions for Nuvectis Pharma and 7 mentions for CervoMed. CervoMed's average media sentiment score of 1.17 beat Nuvectis Pharma's score of 1.09 indicating that CervoMed is being referred to more favorably in the media.
Nuvectis Pharma received 5 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 88.89% of users gave Nuvectis Pharma an outperform vote.
CervoMed's return on equity of -18.31% beat Nuvectis Pharma's return on equity.
Summary
CervoMed beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
